Moderna Price Target Raised To $234 From $208 At Piper Sandler

Smileys, Customer Satisfaction, Review, Feedback

Image Source: Pixabay

Piper Sandler analyst Edward Tenthoff raised the firm's price target on Moderna (MRNA) to $234 from $208 and reiterates an Overweight rating on the shares.

The stock closed Wednesday up 7% to $160.03. The company's vaccine day yesterday focused on SARS-COV-2 vaccine mRNA-1273 with Phase III COVE data out to six months showing over 90% protection against COVID-19 and over 95% protection against severe infection, Tenthoff tells investors in a research note.

The analyst continues to forecast mRNA-1273 revenues of $10.85B in 2021 and $15.75B in 2022. He sees future revenues from complete vaccination in the U.S., overseas vaccinations, and U.S. boosters, noting that Covid-19 is "not going away." Further, Moderna is advancing a "rich pipeline" of mRNA medicines, adds Tenthoff.


Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.